Early tolerability and safety of fingolimod in clinical practice.

ABSTRACT:

Background

Fingolimod is approved by the U.S. Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS. Several screening studies and a first-dose observation (FDO) period are recommended due to adverse effects observed in clinical trials.

Objective

The objective of this study is to describe the early experience with fingolimod, including startup, tolerability and safety in a large academic multiple sclerosis (MS) center.

Methods

Patients prescribed fingolimod from September 2010 to July 2011 were identified through electronic medical records. Demographics, MS disease history, pre-treatment screening studies, FDO experience during shared medical visits and three month follow-up data were analyzed.

Results

Three hundred

SUBMITTER: Ontaneda D 

PROVIDER: S-EPMC3970706 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature